NCT03692143View on ClinicalTrials.gov

Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP

Active, not recruitingOBSERVATIONAL
Enrollment

90

Participants

Timeline

Start Date

January 1, 2017

Primary Completion Date

March 1, 2025

Study Completion Date

December 1, 2030

Conditions
Osteoporosis, PostmenopausalVertebral FractureQuality of Life
Interventions
DRUG

Teriparatide

subcutaneous injection of teriparatide(20 mg) once daily

PROCEDURE

PVP

With local anesthesia, bone cement was injected in to fractured body in a needle that penetrated transpedically and percutaneously

DRUG

Alendronate

Alendronate Sodium, oral, 70mg, once a week

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT03692143 - Comparation of Treatment Strategies for OVF: Teriparatide Injection and PVP | Biotech Hunter | Biotech Hunter